The novel tyrosine kinase inhibitor AKN-028 has significant antileukemic activity in cell lines and primary cultures of acute myeloid leukemia
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The novel tyrosine kinase inhibitor AKN-028 has significant antileukemic activity in cell lines and primary cultures of acute myeloid leukemia
Authors
Keywords
-
Journal
Blood Cancer Journal
Volume 2, Issue 8, Pages e81-e81
Publisher
Springer Nature
Online
2012-08-03
DOI
10.1038/bcj.2012.28
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
- (2012) Jay P. Patel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse
- (2011) M. Levis et al. BLOOD
- Therapeutic Advances in Acute Myeloid Leukemia
- (2011) Alan Burnett et al. JOURNAL OF CLINICAL ONCOLOGY
- Identification of AKN-032, a novel 2-aminopyrazine tyrosine kinase inhibitor, with significant preclinical activity in acute myeloid leukemia
- (2010) Anna Eriksson et al. BIOCHEMICAL PHARMACOLOGY
- FLT3 as a therapeutic target in AML: still challenging after all these years
- (2010) T. Kindler et al. BLOOD
- Cdc2-like Kinase 2 Is an Insulin-Regulated Suppressor of Hepatic Gluconeogenesis
- (2010) Joseph T. Rodgers et al. Cell Metabolism
- Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid Leukemia
- (2010) Farhad Ravandi et al. JOURNAL OF CLINICAL ONCOLOGY
- mTOR signaling is activated by FLT3 kinase and promotes survival of FLT3-mutated acute myeloid leukemia cells
- (2010) Weina Chen et al. Molecular Cancer
- Prognostic factors in AML in relation to (ab)normal karyotype
- (2009) Richard M. Stone BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- Dissecting the role of mTOR: Lessons from mTOR inhibitors
- (2009) Ryan J.O. Dowling et al. BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS
- FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML
- (2009) K. W. Pratz et al. BLOOD
- Acute dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis
- (2009) J. L. Snead et al. BLOOD
- Mechanisms of resistance to FLT3 inhibitors
- (2009) S. Haihua Chu et al. DRUG RESISTANCE UPDATES
- Targeted therapy in acute myeloid leukaemia: current status and future directions
- (2009) Camilla Stapnes et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Use of the in Vivo Hollow Fiber Assay in Natural Products Anticancer Drug Discovery#
- (2009) Qiuwen Mi et al. JOURNAL OF NATURAL PRODUCTS
- Clinical implications of c-Kit mutations in acute myelogenous leukemia
- (2009) Muriel Malaise et al. Current Hematologic Malignancy Reports
- Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry
- (2008) G. Juliusson et al. BLOOD
- The fluorometric microculture cytotoxicity assay
- (2008) Elin Lindhagen et al. Nature Protocols
- JAKs in pathology: Role of Janus kinases in hematopoietic malignancies and immunodeficiencies
- (2008) William Vainchenker et al. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More